Sunitinib-induced reduction in skin microvascular density is a reversible phenomenon.
de Boer
M P
MP
Department of Internal Medicine.
van der Veldt
A A M
AAM
Department of Medical Oncology, VU University Medical Center.
Lankheet
N A
NA
Department of Pharmacy & Pharmacology, Slotervaart Hospital, Amsterdam, The Netherlands.
Wijnstok
N J
NJ
Department of Internal Medicine.
van den Eertwegh
A J M
AJM
Department of Medical Oncology, VU University Medical Center.
Boven
E
E
Department of Medical Oncology, VU University Medical Center. Electronic address: e.boven@vumc.nl.
Serné
E H
EH
Department of Internal Medicine.
D020533:Angiogenesis Inhibitors / Q000494:pharmacology*; D002196:Capillaries / Q000187:drug effects*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D007211:Indoles / Q000494:pharmacology*; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000473:pathology; D010166:Palliative Care; D011758:Pyrroles / Q000494:pharmacology*; D012867:Skin / Q000098:blood supply* / Q000187:drug effects*; D000077210:Sunitinib
D020533:Angiogenesis Inhibitors; D007211:Indoles; D011758:Pyrroles; D000077210:Sunitinib